S 974 · 115th Congress 2017โ€“2019, ended

CREATES Act of 2018

Latest action · Jun 21, 2018 Placed on Senate Legislative Calendar under General Orders. Calendar No. 482.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedApr 27, 2017
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Creating and Restoring Equal Access To Equivalent Samples Act of 2017 or the CREATES Act of 2017

This bill permits the developer of a drug or biological product to bring a civil action against the license holder of an approved drug or biological product if the holder has declined to make available sufficient quantities of the approved drug or product for the developer's testing.

Cosponsors 30

Members who signed on, in the order they did. Signatures ran from Apr 27, 2017 to Aug 22, 2018; 11 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
D-MNAmy KlobucharOriginalApr 27, 2017
R-IAChuck GrassleyOriginalApr 27, 2017
D-MOClaire McCaskillOriginalApr 27, 2017
D-CADianne FeinsteinOriginalApr 27, 2017
R-AZJohn McCainOriginalApr 27, 2017
R-UTMike LeeOriginalApr 27, 2017
D-CTRichard BlumenthalOriginalApr 27, 2017
D-ILRichard J. DurbinOriginalApr 27, 2017
D-RISheldon WhitehouseOriginalApr 27, 2017
R-MESusan M. CollinsOriginalApr 27, 2017
R-ARTom CottonOriginalApr 27, 2017
R-TXTed CruzDec 5, 2017
D-NHMargaret Wood HassanDec 18, 2017
R-KYRand PaulDec 18, 2017
R-LAJohn KennedyFeb 5, 2018

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateJudiciary Committee
Referred Apr 27, 2017Markup Jun 14, 2018Reported Jun 21, 2018

Actions 5

Everything that happened, newest first.

  1. Jun 21, 2018Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
  2. Jun 21, 2018Placed on Senate Legislative Calendar under General Orders. Calendar No. 482.
  3. Jun 14, 2018Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Apr 27, 2017Introduced in Senate
  5. Apr 27, 2017Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S2619)

In the Congressional Record 11

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S7221Chuck Grassley R-IANov 29, 2018
SenateDebate and remarks S5881Robert Menendez D-NJAug 23, 2018
SenateDebate and remarks S807Patrick J. Leahy D-VTFeb 8, 2018
SenateDebate and remarks S7960Amy Klobuchar D-MNDec 12, 2017
SenateDebate and remarks S7181Amy Klobuchar D-MNNov 13, 2017
SenateDebate and remarks S7092Amy Klobuchar D-MNNov 8, 2017
SenateDebate and remarks S6346Amy Klobuchar D-MNOct 5, 2017
SenateDebate and remarks S4148Amy Klobuchar D-MNJul 24, 2017
SenateDebate and remarks S4033Amy Klobuchar D-MNJul 18, 2017
SenateDebate and remarks S3754Amy Klobuchar D-MNJun 26, 2017
SenateDebate and remarks S2619Patrick J. Leahy D-VTApr 27, 2017

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Congressional Budget Office cost estimate

  1. Sep 19, 2018S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2018As reported by the Senate Committee on the Judiciary on June 21, 2018

Printed hearings 3

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
S. Hrg. 115-727PRESCRIPTION DRUG AFFORDABILITY AND INNOVATION: ADDRESSING CHALLENGES IN TODAY'S MARKET215 pagesFinance CommitteeJun 26, 2018
S. Hrg. 115-869THE COST OF PRESCRIPTION DRUGS: AN EXAMINATION OF THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE REPORT "MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE"60 pagesHealth, Education, Labor, and Pensions CommitteeDec 12, 2017
S. Hrg. 115-312HEALTH CARE: ISSUES IMPACTING COST AND COVERAGE117 pagesFinance CommitteeSep 12, 2017

CRS reports 2

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 2

Products on other subjects that cite it, usually among other measures.

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
HR 2212CREATES Act of 2017Identical billApr 28, 2017

Titles 5

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Short Titles as Introduced
CREATES Act of 2017
Creating and Restoring Equal Access To Equivalent Samples Act of 2017
Short Titles as Reported to Senate
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
CREATES Act of 2018

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 2

Each version as it was printed, newest first.

  1. Jun 21, 2018Reported to Senate
  2. Apr 27, 2017Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.